USAgainstAlzheimer’s is proud to work with a network of organizations that serve the Alzheimer’s community and support innovative Alzheimer’s research and drug discovery. We believe that the only way to advance strategies that will stop Alzheimer’s is to facilitate communication and collaboration between the private, public and non-profit sectors.
USAgainstAlzheimer’s co-convenes the Leaders Engaged On Alzheimer’s Disease Coalition (LEAD) with the Alzheimer’s Foundation of America.
USAgainstAlzheimer’s is the convener and organizer of The Global CEO Initiative on Alzheimer’s Disease.
USAgainstAlzheimer’s is a founding partner of the 21st Century BrainTrustTM.
The Global Alzheimer’s Platform (GAP) Foundation joins together leading academic researchers, pharmaceutical companies, nonprofit organizations and foundations, and governments around the world to reduce the time, cost and risk of Alzheimer’s clinical trials in order to speed innovative medicines to those with or at risk of Alzheimer’s disease. The GAP Foundation is establishing a standing global trial-ready platform to drive quality, efficiency, and innovation in Alzheimer’s Clinical Trials, seeking to reduce clinical testing cycle times by two years or more and to achieve greater uniformity in trial populations. It is doing that by building large, well-characterized trial-ready cohorts, a network of certified high-performance clinical trial sites, and an adaptive proof-of-concept trial mechanism.